Phrixus’s management team and board of directors have experience in both major pharmaceutical companies and entrepreneurial biotechnology companies.
Latest News
- FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
- Carmeseal-MD™, the first disease-modifying agent for skeletal limb muscle, diaphragm and heart
- Independent study confirms hypothesized mechanism of action for Carmeseal-MD™ (P-188 NF) as membrane sealant on dystrophic cells
- Carmeseal-MD™ (P-188 NF) improves respiratory and cardiac dysfunction in dystrophic mice after subcutaneous administration
- Phrixus Pharmaceuticals Receives Services from NIH
- Phrixus Pharmaceuticals Announces European Access Program
- Phrixus Pharmaceuticals Announces SMARTT/NHLBI Award
- Phrixus Pharmaceuticals Announces Funding by DuchenneDashboard
- Phrixus Pharmaceuticals Reports Positive Preclinical Results
- Phrixus Pharmaceuticals Announces $623,000 in NIH Funding
- Phrixus Pharmaceuticals Announces $890,000 in NIH Funding
- Start-Up Magazine Emerging Company Profile
- Phrixus Pharmaceuticals Announces Orphan Drug Designation